Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
RESEARCH TOOLSreports
BCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.33 - $55.95
Previous Close$0.41
Volume996.24K
Average Volume (3M)653.33K
Market Cap
C$18.78M
Enterprise Value$22.37M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 27, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 05, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-13.27
Shares Outstanding3,709,437
10 Day Avg. Volume248,252
30 Day Avg. Volume653,328
Standard Deviation0.27
R-Squared0.10
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.12Price Target Upside626.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe first patient treated in the Phase 1 trial with Bria-OTS achieved resolution of a lung metastasis, showing early effectiveness of the treatment.
Market ExpectationsThe reverse stock split and model update led to an increased price target of $32, showing improved market expectations for the stock.
Bears Say
Financial ChallengesThe company is expected to need to raise additional capital, indicating financial challenges that may affect operations.
---
Ownership Overview
68.55% Insiders
0.19% Mutual Funds
<0.01% Other Institutional Investors
31.25% Public Companies and
Individual Investors
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $3.33 and its highest was $55.95 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$18.78M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Mar 27, 2025 which is in 33 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Dec 16, 2024. The company reported -$3.145 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.145.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Undervalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp pays a Notavailable dividend of $0.063 which represents an annual dividend yield of N/A. See more information on BriaCell Therapeutics Corp dividends here
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 3,709,437 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$3.145 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.173%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
---
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
---
BCTX Stock 12 Month Forecast
Average Price Target
$32.12
▲(626.63% Upside)
Technical Analysis
Oncolytics Biotech
―
Medicenna Therapeutics Corp
―
Solaris Resources
―
KDA Group Inc.
―
Best Analysts Covering BCTX
1 Year
1 Year Success Rate
3/23 ratings generated profit
1 Year Average Return
-51.69%
reiterated a buy rating 20 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 13.04% of your transactions generating a profit, with an average return of -51.69% per trade.
---